These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 19449283

  • 1. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis.
    Domrongkitchaiporn S, Disthabanchong S, Cheawchanthanakij R, Niticharoenpong K, Stitchantrakul W, Charoenphandhu N, Krishnamra N.
    Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):105-12. PubMed ID: 19449283
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chronic metabolic acidosis increases the serum concentration of 1,25-dihydroxyvitamin D in humans by stimulating its production rate. Critical role of acidosis-induced renal hypophosphatemia.
    Krapf R, Vetsch R, Vetsch W, Hulter HN.
    J Clin Invest; 1992 Dec; 90(6):2456-63. PubMed ID: 1469097
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [Abstract] [Full Text] [Related]

  • 6. Regulation of fibroblast growth factor-23 in chronic kidney disease.
    Westerberg PA, Linde T, Wikström B, Ljunggren O, Stridsberg M, Larsson TE.
    Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
    [Abstract] [Full Text] [Related]

  • 7. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
    Tomida K, Hamano T, Ichimaru N, Fujii N, Matsui I, Nonomura N, Tsubakihara Y, Rakugi H, Takahara S, Isaka Y.
    Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
    [Abstract] [Full Text] [Related]

  • 8. Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice.
    Tomoe Y, Segawa H, Shiozawa K, Kaneko I, Tominaga R, Hanabusa E, Aranami F, Furutani J, Kuwahara S, Tatsumi S, Matsumoto M, Ito M, Miyamoto K.
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1341-50. PubMed ID: 20357029
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
    Yamamoto T, Imanishi Y, Kinoshita E, Nakagomi Y, Shimizu N, Miyauchi A, Satomura K, Koshiyama H, Inaba M, Nishizawa Y, Jüppner H, Ozono K.
    J Bone Miner Metab; 2005 Jun; 23(3):231-7. PubMed ID: 15838626
    [Abstract] [Full Text] [Related]

  • 11. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J, Liu S, Quarles LD.
    Semin Dial; 2007 Jun; 20(4):302-8. PubMed ID: 17635819
    [Abstract] [Full Text] [Related]

  • 12. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis.
    Ambühl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U.
    Am J Kidney Dis; 1999 Nov; 34(5):875-83. PubMed ID: 10561144
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function.
    Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L.
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):35-42. PubMed ID: 17201799
    [Abstract] [Full Text] [Related]

  • 15. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T.
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [Abstract] [Full Text] [Related]

  • 16. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ, Liu S, Indridason OS, Quarles LD.
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [Abstract] [Full Text] [Related]

  • 17. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y.
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [Abstract] [Full Text] [Related]

  • 18. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
    Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG.
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
    [Abstract] [Full Text] [Related]

  • 19. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
    Barros X, Torregrosa JV, Martínez de Osaba MJ, Casals G, Paschoalin R, Durán CE, Campistol JM.
    Transplantation; 2012 Oct 27; 94(8):830-6. PubMed ID: 23018879
    [Abstract] [Full Text] [Related]

  • 20. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure.
    Lu KC, Lin SH, Yu FC, Chyr SH, Shieh SD.
    Miner Electrolyte Metab; 1995 Oct 27; 21(6):398-402. PubMed ID: 8592483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.